Why the study?
Does rofecoxib improve symptoms and alter the risk of gastrointestinal and cardiovascular events compared to placebo or naproxen in patients with rheumatoid arthritis?
Does rofecoxib improve symptoms and alter the risk of gastrointestinal and cardiovascular events compared to placebo or naproxen in patients with rheumatoid arthritis?
Rofecoxib is associated with a significantly increased risk of cardiovascular events and myocardial infarction compared to naproxen, which led to its global market withdrawal.
No takes yet. Share an insight, caveat, or question.
Rofecoxib's excess CV risk versus naproxen precludes use; confirms withdrawal rationale and challenges coxib safety in arthritis.
Garner et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: